PBAC Public Summary Documents - August 2018

Page last updated: 31 January 2020

Public Summary Documents relating to the August 2018 PBAC meeting.

• Budesonide with Eformoterol, Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses; Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 120 doses DuoResp® Spiromax®, Teva Pharma Australia Pty Limited
• Meningococcal (groups A, C, W-135 and Y) Oligosaccharide CRM 197 Conjugate Vaccine Pre-filled syringe, 0.5mL, Menveo®, GlaxoSmithKline Australia Pty Ltd
• Meningococcal Polysaccharide Conjugate Vaccine Serogroups A, C, W-135 and Y Pre-filled syringe, 0.5mL, Nimenrix ®, Pfizer Australia Pty Ltd.